476 related articles for article (PubMed ID: 27616553)
21. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
[TBL] [Abstract][Full Text] [Related]
22. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Goy A; Sinha R; Williams ME; Kalayoglu Besisik S; Drach J; Ramchandren R; Zhang L; Cicero S; Fu T; Witzig TE
J Clin Oncol; 2013 Oct; 31(29):3688-95. PubMed ID: 24002500
[TBL] [Abstract][Full Text] [Related]
23. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.
Landsburg DJ; Hughes ME; Koike A; Bond D; Maddocks KJ; Guo L; Winter AM; Hill BT; Ondrejka SL; Hsi ED; Nasta SD; Svoboda J; Schuster SJ; Bogusz AM
Blood Adv; 2019 Jan; 3(2):132-135. PubMed ID: 30651281
[TBL] [Abstract][Full Text] [Related]
25. Ibrutinib for mantle cell lymphoma.
Tucker DL; Rule SA
Future Oncol; 2016 Feb; 12(4):477-91. PubMed ID: 26759179
[TBL] [Abstract][Full Text] [Related]
26. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
27. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
28. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.
UK CLL Forum
Haematologica; 2016 Dec; 101(12):1563-1572. PubMed ID: 27756834
[TBL] [Abstract][Full Text] [Related]
29. Novel therapies for relapsed/refractory mantle cell lymphoma.
Arora PC; Portell CA
Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Kirschbaum M; Frankel P; Popplewell L; Zain J; Delioukina M; Pullarkat V; Matsuoka D; Pulone B; Rotter AJ; Espinoza-Delgado I; Nademanee A; Forman SJ; Gandara D; Newman E
J Clin Oncol; 2011 Mar; 29(9):1198-203. PubMed ID: 21300924
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece.
Dimou M; Iliakis T; Pardalis V; Bitsani C; Vassilakopoulos TP; Angelopoulou M; Tsaftaridis P; Papaioannou P; Koudouna A; Kalyva S; Kyrtsonis MC; Panayiotidis P
Leuk Lymphoma; 2019 Dec; 60(12):2939-2945. PubMed ID: 31184241
[TBL] [Abstract][Full Text] [Related]
32. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
[TBL] [Abstract][Full Text] [Related]
33. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
[TBL] [Abstract][Full Text] [Related]
34. Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study.
Huang X; Qiu L; Jin J; Zhou D; Chen X; Hou M; Hu J; Hu Y; Ke X; Li J; Liang Y; Liu T; Lv Y; Ren H; Sun A; Wang J; Zhao C; Salman M; Sun S; Howes A; Wang J; Wu P; Li J
Cancer Med; 2018 Apr; 7(4):1043-1055. PubMed ID: 29533000
[TBL] [Abstract][Full Text] [Related]
35. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Awan FT; Schuh A; Brown JR; Furman RR; Pagel JM; Hillmen P; Stephens DM; Woyach J; Bibikova E; Charuworn P; Frigault MM; Hamdy A; Izumi R; Linghu B; Patel P; Wang MH; Byrd JC
Blood Adv; 2019 May; 3(9):1553-1562. PubMed ID: 31088809
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
Jain P; Kanagal-Shamanna R; Zhang S; Ahmed M; Ghorab A; Zhang L; Ok CY; Li S; Hagemeister F; Zeng D; Gong T; Chen W; Badillo M; Nomie K; Fayad L; Medeiros LJ; Neelapu S; Fowler N; Romaguera J; Champlin R; Wang L; Wang ML
Br J Haematol; 2018 Nov; 183(4):578-587. PubMed ID: 30175400
[TBL] [Abstract][Full Text] [Related]
37. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).
Jain P; Romaguera J; Srour SA; Lee HJ; Hagemeister F; Westin J; Fayad L; Samaniego F; Badillo M; Zhang L; Nastoupil L; Kanagal-Shamanna R; Fowler N; Wang ML
Br J Haematol; 2018 Aug; 182(3):404-411. PubMed ID: 29785709
[TBL] [Abstract][Full Text] [Related]
38. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
Kim ES; Dhillon S
Drugs; 2015 May; 75(7):769-76. PubMed ID: 25802231
[TBL] [Abstract][Full Text] [Related]
39. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
40. Ibrutinib for the treatment of mantle cell lymphoma.
Shah N; Hutchinson C; Rule S
Expert Rev Hematol; 2014 Oct; 7(5):521-31. PubMed ID: 25158606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
